Share on LinkedInShare on LinkedIn

ARTICLE · 10 NOVEMBER 2016

Canadian Patent Term Extension - Bill Is In The House

Canada and Europe finally signed off on the CETA. Its most significant aspect for the pharma industry is prospect of increased drug patent terms by up to 2 years.

CanadaIntellectual Property

Canada and Europe finally signed off on the Comprehensive Economic and Trade Agreement ("CETA"). Its most significant aspect for the pharma industry is prospect of increased drug patent terms by up to 2 years. Not long after the ink was dry on CETA, an amendment (implementation) Bill was introduced into Canadian Parliament on October 31, 2016. This Bill is the first concrete domestic legislative step toward becoming a law1.

Background on CETA

CETA was the product of several years of negotiations. It is a wide-ranging trade agreement covering diverse topics such as foreign ownership and investments, access to public procurement contracts, automobiles, food (e.g. beef and dairy products) and agriculture. Pharmaceuticals were also a prominent part of the discussion.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from